The hearings on Capitol Hill about drug prices were a big deal this week. To policy wonks. All the rage was the report by the National Academies of Sciences about policies to lower drug prices. There was lot of intriguing discussion, debate, and deliberation on things we should do. Many that I agree with! Blah, blah, blah, blah. Medicare should negotiate drug prices! We should make generics available quicker! We should clamp down on patent abuse by big pharma! More price transparency! Stop direct-to-consumer advertising! Blah, blah, blah…blah. All of this was a big deal. To policy wonks.
What about people today?!??!
Now I like talking policy – too much sometimes. But I’m not writing about that hearing. No way. I came across a little piece in the New York Times, which loudly reminded me of this fact: While Congress debates, activists act, and policy nuts pontificate on drug prices –foreign pharmacies are the solution that saves American lives NOW. This is indisputable.
Access to more affordable drugs keeps Americans out of the hospital, able to lead more productive lives – and living. That’s what the most conclusive research proves.
For that reason: There’s no doubt in my mind that properly verified Canadian and other foreign online pharmacies are a boon to public health because they are far cheaper than U.S. pharmacies. Just to be clear: It’s not just that they help Americans save hundreds of millions of dollars a year – maybe billions (wish I knew). They are saving lives. (more…)
Tagged with: Commonwealth Fund, Congress, FDA, Hearings, Medication Adherence, National Academy of Sciences
For years, the National Association of Boards of Pharmacy (NABP) has opposed new drug importation proposals that would improve access to more affordable medication from Canada and other countries. Led by its executive director, Carmen Catizone, PharmD, the NABP’s efforts pertaining to drug importation have focused mostly on opposing online access to imported medications – meaning Americans getting cheaper meds from Canada and other countries. This is not surprising. NABP has received a lot of money from pharmaceutical companies for these efforts. Also, NABP represents U.S. pharmacy boards and the members of those boards often have financial interests in U.S. pharmacies. But here’s a surprise…
Earlier this week, an article in the Washington Post focused on various prescription drug importation programs offered by cities, counties and schools to lower pharmaceutical bills for retirees and municipalities. According to the article, the FDA may view these programs as illegal. The FDA recently raided some pharmacy storefronts in Florida but did not shut them down. Those programs help Americans—especially the elderly— order affordable medications from other countries. Operating for 10, some even 15 years without interruption, they continue to save millions of dollars a year.
Mr. Catizone had the last word in the article. (more…)
Tagged with: Carmen Catizone, drug importation program, Flagler, Kokomo, NABP, Schenectady
Alex Azar and Eli Lilly have opposed policies that would make healthcare more affordable for Americans. Photo: Michael Reynolds/EPA
As I wrote a few weeks back on these blog pages, President Trump’s nomination of Alex Azar to lead the Department of Health and Human Services will help Big Pharma continue to get away with murder; something the president says he opposes. Mr. Azar just left Eli Lilly USA earlier this year as its president. Under his tenure with Lilly, Azar vehemently opposed importing lower-cost medications from Canada among other polices to tackle high drug prices.
In my capacity as founder of Prescription Justice, I published an op-ed in The Guardian called “Alex Azar is big pharma personified. He must not become US health secretary.” A Big Pharma executive is not the right pick to get this country moving on lowering drug prices. I’m just saying…
Tagged with: Alex Azar, Big Pharma, Drug Importation, Eli Lilly, HHS